You are here

Acceleron

Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS

Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS

Pharmaceutical Business Review

Bristol-Myers Squibb

myelodysplastic syndromes

Flag link:

FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease

FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease

BioSpace

beta thalassemia

Flag link:

Another failed midstage asset for Acceleron, another pipeline test dumped

Another failed midstage asset for Acceleron, another pipeline test dumped

Fierce Biotech

clinical trials

Flag link:

Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension

Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension

Pharmaceutical Business Review

Flag link:

In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful

In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful

Fierce Biotech

Bristol-Myers Squibb

beta thalassemia

Flag link:

Celgene and Acceleron Submit BLA for Luspatercept

Celgene and Acceleron Submit BLA for Luspatercept

CP Wire

myelodysplastic syndrome

beta thalassemia

Flag link:

Celgene and Acceleron Submit BLA for Luspatercept

Flag link:

Acceleron, Stemline price upsized follow-ons

Acceleron, Stemline price upsized follow-ons

BioCentury

Stemline Therapeutics

Elzonris tagraxofusp-erzs

Flag link:

Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

Xconomy

Juno Therapeutics

Kite Therapeutics

Agios Pharmaceuticals

Jounce Therapeutics

Flag link:

BMS deal weighs on Celgene partners

BMS deal weighs on Celgene partners

BioCentury

Bristol-Myers Squibb

Flag link:

Top Biotech Stocks to Watch at ASH 2018

Top Biotech Stocks to Watch at ASH 2018

Yahoo/Motley Fool

Flag link:

3 Cancer Stocks to Watch in December

3 Cancer Stocks to Watch in December

Motley Fool

Flag link:

Here's Why Acceleron Pharma Inc. Lost 10.2% in July

Here's Why Acceleron Pharma Inc. Lost 10.2% in July

Yahoo/Motley Fool

clinical trials

Flag link:

A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept

A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept

Endpoints

beta thalassemia

Flag link:

Acceleron blood disease drug hits goal in pivotal clinical trial

Acceleron blood disease drug hits goal in pivotal clinical trial

Stat

clinical trials

myelodysplastic syndrome

Flag link:

Billions of Dollars on the Line for Celgene With These 3 Small Biotechs

Billions of Dollars on the Line for Celgene With These 3 Small Biotechs

Motley Fool

Juno Therapeutics

Flag link:

Phase II Fail Prompts Acceleron to Discontinue Development of Renal Cell Carcinoma Drug

Phase II Fail Prompts Acceleron to Discontinue Development of Renal Cell Carcinoma Drug

Xtalks

renal cell carcinoma

clinical trials

Flag link:

Acceleron dumps dalantercept after kidney cancer trial fail

Acceleron dumps dalantercept after kidney cancer trial fail

Fierce Biotech

clinical trials

Flag link:

The Most Important Keys To Celgene's Pipeline

The Most Important Keys To Celgene's Pipeline

Seeking Alpha

Juno Therapeutics

Flag link:

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Yahoo

myelodysplastic syndromes

Flag link:

Pages